Breaking News, Financial News

Financial Report: PDL BioPharma

Royalty revenues up 19% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

PDL BioPharma 1Q Revenues: $91.8 million (+19%) 1Q Earnings: $53.5 million (+33%) Comments: Royalty revenues were up 19% driven by increased royalties from Avastin, Herceptin, Lucentis, Tysabri, and Actemra....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters